These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2355949)

  • 1. Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome.
    Silbert PL; Hankey GJ; Barr AL
    Muscle Nerve; 1990 Apr; 13(4):360-1. PubMed ID: 2355949
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lambert-Eaton myasthenic syndrome].
    Sahashi K
    Nihon Rinsho; 1990 Jul; 48(7):1477-82. PubMed ID: 2402065
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison.
    Jost WH; Mielke U; Schimrigk K
    Wien Klin Wochenschr; 1991; 103(20):629-32. PubMed ID: 1763511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.
    Oh SJ; Kim DS; Head TC; Claussen GC
    Muscle Nerve; 1997 Sep; 20(9):1146-52. PubMed ID: 9270671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current therapy of the Lambert-Eaton myasthenic syndrome.
    Lundh H; Nilsson O; Rosén I
    Prog Brain Res; 1990; 84():163-70. PubMed ID: 2267294
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome].
    Yuste Ara JR; Beloqui Ruiz O; Artieda Gonzalez-Granda J; Herrero Santos JI; De la Peña Fernandez A; Prieto Valtueña J
    An Med Interna; 1996 Jan; 13(1):25-6. PubMed ID: 8679819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy.
    Cooke JD; Hefter H; Brown SH; Toyka KV; Freund HJ
    Electromyogr Clin Neurophysiol; 1994 Mar; 34(2):87-93. PubMed ID: 8187683
    [No Abstract]   [Full Text] [Related]  

  • 8. [The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine].
    Casanova B; Vílchez JJ; Rubio P
    Rev Clin Esp; 1993 Apr; 192(7):354-5. PubMed ID: 8388576
    [No Abstract]   [Full Text] [Related]  

  • 9. [The drug treatment of the Lambert-Eaton myasthenic syndrome].
    Danilov AF
    Eksp Klin Farmakol; 1999; 62(6):69-71. PubMed ID: 10650534
    [No Abstract]   [Full Text] [Related]  

  • 10. Guanidine and germine in Eaton-Lambert syndrome.
    Cherington M
    Neurology; 1976 Oct; 26(10):944-6. PubMed ID: 986585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SFEMG improvement with remission in the cancer-associated Lambert-Eaton myasthenic syndrome.
    Oh SJ
    Muscle Nerve; 1989 Oct; 12(10):844-8. PubMed ID: 2558313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome.
    Peterlin BL; Flood W; Kothari MJ
    J Am Osteopath Assoc; 2002 Dec; 102(12):682-4. PubMed ID: 12501987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
    Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient neutropenia in a patient receiving cimetidine.
    Ufberg MH; Brooks CM; Bosanac PR; Kintzel JE
    Gastroenterology; 1977 Sep; 73(3):635-8. PubMed ID: 892366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lambert-Eaton syndrome].
    Osterhage J; Jost WH; Schimrigk K
    Med Klin (Munich); 1996 Aug; 91(8):526-30. PubMed ID: 8965753
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neutropenia in a patient treated with cimetidine].
    Dubost JL; Chevallier H; Sultan R; Fallouh H
    Med Chir Dig; 1980; 9(6):523-4. PubMed ID: 7206864
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
    Morata C; Alfaro A; Chumillas MJ; Montalar J
    Med Clin (Barc); 1995 Feb; 104(4):156. PubMed ID: 7898163
    [No Abstract]   [Full Text] [Related]  

  • 18. A diagnostic and management dilemma: combined paraneoplastic myasthenia gravis and Lambert-Eaton myasthenic syndrome presenting as acute respiratory failure.
    Roohi F; Smith PR; Bergman M; Baig MA; Sclar G
    Neurologist; 2006 Nov; 12(6):322-6. PubMed ID: 17122730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cimetidine-induced neutropenia: a possible dose-related phenomenon.
    Posnett DN; Stein RS; Graber SE; Krantz SB
    Arch Intern Med; 1979 May; 139(5):584-6. PubMed ID: 312628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction.
    Pellkofer HL; Voltz R; Kuempfel T
    Muscle Nerve; 2009 Aug; 40(2):305-8. PubMed ID: 19609921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.